QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF For Our Patients Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Setter, S. M Articles by Baker, D. E Search for Related Content PubMed PubMed Citation Articles by Setter, S. M Articles by Baker, D. E

SEXUAL HEALTH

Phosphodiesterase 5 Inhibitors for Erectile Dysfunction

Associate Professor, Department of Pharmacotherapy, College of Pharmacy, Washington State University/Elder Services, Spokane, WA

Jason L Iltz, PharmD

Clinical Assistant Professor, Department of Pharmacotherapy, College of Pharmacy, Washington State University; Clinical Pharmacy Specialist, Group Health Cooperative, Spokane

Jack E Fincham, PhD

AW Jowdy Professor of Pharmacy Care, College of Pharmacy, University of Georgia, Athens, GA

R Keith Campbell, BSPharm MBA CDE FASHP

Professor, Department of Pharmacotherapy, College of Pharmacy, Washington State University

Danial E Baker, PharmD

Professor, Department of Pharmacotherapy, College of Pharmacy, Washington State University

Reprints: Dr. Setter, Department of Pharmacotherapy, College of Pharmacy, Washington State University/Elder Services, 5125 N. Market St., Spokane, WA 99217-6131, fax 509/458-7459, ssetter{at}smhca.org

OBJECTIVE: To review the pharmacologic and clinical trial data of the Food and Drug Administration–approved phosphodiesterase 5 (PDE5) inhibitors for the treatment of erectile dysfunction (ED).

DATA SOURCES: Primary research and review articles were identified through a search of ScienceDirect, PubMed/MEDLINE, and International Pharmaceutical Abstracts (1990–August 2004). The following search terms were used in the Medicine Dentistry and Pharmacology, Toxicology, and Pharmaceutical Sciences subcategories: phosphodiesterase 5 inhibitor, PDE5 inhibitor, erectile dysfunction, sildenafil, vardenafil, tadalafil, prostatectomy, and diabetes. Web of Science (1990–August 2004) was used to search for additional abstracts using the same search terms as above. The package inserts for sildenafil, vardenafil, and tadalafil were also consulted.

STUDY SELECTION AND DATA EXTRACTION: All identified research, review articles, and abstracts were assessed for relevance, and all relevant information was included. Priority was given to the primary medical literature and clinical trial reports.

DATA SYNTHESIS: ED is a common disorder in males with increased prevalence associated with age and presence of cardiovascular disease, prostatectomy, or diabetes mellitus. Sildenafil, vardenafil, and tadalafil are selective PDE5 inhibitors currently available for treatment of ED. Their pharmacology and pharmacokinetics vary slightly, but with potentially important clinical differences in duration of activity; all have similar clinical efficacy and adverse effect profiles in patients with ED of various causes.

CONCLUSIONS: Sildenafil, vardenafil, and tadalafil are safe and effective PDE5 inhibitors for the treatment of ED.

Key Words: erectile dysfunction, phosphodiesterase inhibitors: sildenafil, tadalafil, vardenafil

Published Online, June 7, 2005. www.theannals.com, DOI 10.1345/aph.1E487

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-05-023-H01

This article has been cited by other articles:

				H. Wang, M. Ye, H. Robinson, S. H. Francis, and H. Ke Conformational Variations of Both Phosphodiesterase-5 and Inhibitors Provide the Structural Basis for the Physiological Effects of Vardenafil and Sildenafil Mol. Pharmacol., January 1, 2008; 73(1): 104 - 110. [Abstract] [Full Text] [PDF]

				T. J. Bivalacqua, W. Deng, M. Kendirci, M. F. Usta, C. Robinson, B. K. Taylor, S. N. Murthy, H. C. Champion, W. J. G. Hellstrom, and P. J. Kadowitz Mesenchymal stem cells alone or ex vivo gene modified with endothelial nitric oxide synthase reverse age-associated erectile dysfunction Am J Physiol Heart Circ Physiol, March 1, 2007; 292(3): H1278 - H1290. [Abstract] [Full Text] [PDF]

				P. Serafini, K. Meckel, M. Kelso, K. Noonan, J. Califano, W. Koch, L. Dolcetti, V. Bronte, and I. Borrello Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function J. Exp. Med., November 27, 2006; 203(12): 2691 - 2702. [Abstract] [Full Text] [PDF]

				A. T. Bender and J. A. Beavo Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use Pharmacol. Rev., September 1, 2006; 58(3): 488 - 520. [Abstract] [Full Text] [PDF]